Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Clinical trial

NCT05732831

1 development in the corpus

NCT05732831

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · PHASE 1/2 TRIAL

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

ClinicalTrials.gov

This is a first-in-human, Phase 1/2 open-label dose escalation and expansion study with no results yet posted; only design and planned enrollment are available.

PreliminaryNCT05732831 Locally Advanced Solid Tumor Pembrolizumab

Reported

Estimated enrollment225

Phase 1 primary outcome (MTD asse…28 days and 21 days

Phase 1 primary outcome (dosing s…28 days

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support